Methods for treating congenital disorders of glycosylation

Abstract

The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation.

1 .- 37 . (canceled) 
     
     
         38 . A method for treating a congenital disorder of glycosylation in a patient in need thereof comprising administering a therapeutically effective amount of an aldose reductase inhibitor. 
     
     
         39 . (canceled) 
     
     
         40 . A method for treating phosphomannomutase deficiency in a patient in need thereof comprising administering a therapeutically effective amount of an aldose reductase inhibitor. 
     
     
         41 . (canceled) 
     
     
         42 . The method of  claim 38 , wherein the aldose reductase inhibitor is epalrestat. 
     
     
         43 . The method of  claim 38 , wherein the patient is further administered a therapeutically effective amount of another therapeutic agent, wherein the another therapeutic agent is an aldose reductase inhibitor. 
     
     
         44 . The method of  claim 43 , wherein the another therapeutic agent is selected from: α-cyano-4-hydroxycinnamic acid, alrestatin, fidarestat, imirestat, lidorestat, minalrestat, ponalrestat, ranirestat, sorbinil, tolrestat, zenarestat, zopolrestat, epalrestat, and rhetsinine, or a pharmaceutically acceptable salt thereof. 
     
     
         45 . The method of  claim 38 , wherein the congenital disorder of glycosylation is a N-linked glycosylation disorder. 
     
     
         46 . The method of  claim 38 , wherein the aldose reductase inhibitor is a compound, or a pharmaceutically acceptable salt thereof, having a —CO 2 H group and an aromatic ring. 
     
     
         47 . The method of  claim 40 , wherein the aldose reductase inhibitor is a compound, or a pharmaceutically acceptable salt thereof, having a —CO 2 H group and an aromatic ring. 
     
     
         48 . The method of  claim 45 , wherein the aldose reductase inhibitor is a compound, or a pharmaceutically acceptable salt thereof, having a —CO 2 H group and an aromatic ring. 
     
     
         49 . The method of  claim 47 , wherein the patient is further administered a therapeutically effective amount of another therapeutic agent, wherein the another therapeutic agent is an aldose reductase inhibitor. 
     
     
         50 . The method of  claim 38 , wherein the aldose reductase inhibitor is administered as a pharmaceutical composition. 
     
     
         51 . The method of  claim 40 , wherein the aldose reductase inhibitor is administered as a pharmaceutical composition. 
     
     
         52 . The method of  claim 50 , wherein the pharmaceutical composition is formulated to provide a sustained or delayed release of the aldose reductase inhibitor. 
     
     
         53 . The method of  claim 51 , wherein the pharmaceutical composition is formulated to provide a sustained or delayed release of the aldose reductase inhibitor. 
     
     
         54 . The method of  claim 38 , wherein the aldose reductase inhibitor is administered once, twice, or three times daily. 
     
     
         55 . The method of  claim 40 , wherein the aldose reductase inhibitor is administered once, twice, or three times daily.